Skip to Content
MilliporeSigma

Key Documents

View All Documentation

Skip To

S9070

SB 220025 trihydrochloride

≥98% (HPLC), solid

Synonym(s):

5-(2-Aminopyrimidin-4-yl)-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole trihydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Size/SKUAvailabilityPrice
2 mg
Check Cart for Availability
$478.00

About This Item

Empirical Formula (Hill Notation):
C18H19FN6 · 3HCl
CAS Number:
197446-75-6
Molecular Weight:
447.76
NACRES:
NA.77
PubChem Substance ID:
24724623
UNSPSC Code:
12352200
MDL number:
MFCD08705333
Assay:
≥98% (HPLC)
Form:
solid

$478.00

Check Cart for Availability
​
Request a Custom Order
​
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Segment

assay

≥98% (HPLC)

form

solid

color

white

solubility

H2O: 22 mg/mL

originator

GlaxoSmithKline

SMILES string

Cl[H].Cl[H].Cl[H].Nc1nccc(n1)-c2c(ncn2C3CCNCC3)-c4ccc(F)cc4

InChI

1S/C18H19FN6.3ClH/c19-13-3-1-12(2-4-13)16-17(15-7-10-22-18(20)24-15)25(11-23-16)14-5-8-21-9-6-14;;;/h1-4,7,10-11,14,21H,5-6,8-9H2,(H2,20,22,24);3*1H

InChI key

IPFBHUGKKONHFR-UHFFFAOYSA-N

Application

SB 220025 trihydrochloride may be used in p38-mediated cell signaling studies.

Biochem/physiol Actions

SB 220025 is a potent, specific inhibitor of human p38 MAP kinase (IC50 = 60 nM).
SB 220025 is a potent, specific inhibitor of human p38 mitogen-activated protein (MAP) kinase, with an IC50 value of 60 nM and 50- to 1000-fold selectivity. SB 220025 reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 reduced the lipopolysaccharide-induced production of TNF at an ED50 value of 7.5 mg/kg. At 30 mg/kg, SB 220025 reduced the expression of TNF and inhibited angiogenesis by ~40%. In a further study, the effects of p38/CSBP MAP kinase inhibition in angiogenesis-dependent chronic inflammatory disease was tested in murine collagen-induced arthritis and SB 220025 was able to prevent the progression of established arthritis.

Features and Benefits

This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
559408S5192
SB 220025 trihydrochloride ≥98% (HPLC), solid

Sigma-Aldrich

S9070

SB 220025 trihydrochloride

SB 220025, Trihydrochloride

Sigma-Aldrich

559408

SB 220025, Trihydrochloride

SB 222200 ≥98% (HPLC), solid

Sigma-Aldrich

S5192

SB 222200

description

≥98% (HPLC), solid

description

-

description

≥98% (HPLC), solid

form

solid

form

white solid

form

solid

assay

≥98% (HPLC)

assay

-

assay

≥98% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

solubility

H2O: 22 mg/mL

solubility

soluble (H2O (22 mg/ml))

solubility

H2O: insoluble, DMSO: soluble ~28 mg/mL

color

white

color

-

color

light yellow

originator

GlaxoSmithKline

originator

-

originator

GlaxoSmithKline

Storage Class

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

PPE (personal protective equipment)

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Questions

Reviews

No rating value

Active Filters